Prescott General Partners’s Lineage Cell Therapeutics LCTX Stock Holding History

Prescott General Partners’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-386,000	Closed	-$194K	–	11
2024 Q4	$194K	Hold	386,000	–	–	0.01%	9
2024 Q3	$349K	Sell	386,000 -234,000	-38%	-$217K	0.02%	9
2024 Q2	$618K	Sell	620,000 -1,231,851	-67%	-$1.36M	0.04%	9
2024 Q1	$2.74M	Hold	1,851,851	–	–	0.15%	6
2023 Q4	$2.02M	Hold	1,851,851	–	–	0.12%	7
2023 Q3	$2.19M	Hold	1,851,851	–	–	0.14%	8
2023 Q2	$2.61M	Hold	1,851,851	–	–	0.16%	8
2023 Q1	$2.78M	Hold	1,851,851	–	–	0.22%	8
2022 Q4	$2.17M	Hold	1,851,851	–	–	0.18%	8
2022 Q3	$2.09M	Hold	1,851,851	–	–	0.16%	8
2022 Q2	$2.93M	Hold	1,851,851	–	–	0.2%	8
2022 Q1	$2.85M	Hold	1,851,851	–	–	0.13%	10
2021 Q4	$4.54M	Hold	1,851,851	–	–	0.16%	9
2021 Q3	$4.67M	Hold	1,851,851	–	–	0.16%	9
2021 Q2	$5.28M	Hold	1,851,851	–	–	0.17%	8
2021 Q1	$4.35M	Hold	1,851,851	–	–	0.15%	9
2020 Q4	$3.26M	Hold	1,851,851	–	–	0.14%	9
2020 Q3	$1.73M	Hold	1,851,851	–	–	0.07%	9
2020 Q2	$1.61M	Hold	1,851,851	–	–	0.07%	9
2020 Q1	$1.53M	Hold	1,851,851	–	–	0.13%	8
2019 Q4	$1.65M	Hold	1,851,851	–	–	0.07%	9
2019 Q3	$1.81M	Hold	1,851,851	–	–	0.07%	9
2019 Q2	$2.04M	Hold	1,851,851	–	–	0.08%	9
2019 Q1	$2.43M	Hold	1,851,851	–	–	0.1%	9
2018 Q4	$1.69M	Sell	1,851,851 -264,815	-13%	-$406K	0.07%	10
2018 Q3	$4.35M	Hold	2,116,666	–	–	0.15%	10
2018 Q2	$3.81M	Hold	2,116,666	–	–	0.14%	10
2018 Q1	$4.98M	Hold	2,116,666	–	–	0.21%	10
2017 Q4	$3.98M	Hold	2,116,666	–	–	0.18%	10
2017 Q3	$5.26M	Hold	2,116,666	–	–	0.27%	10
2017 Q2	$5.83M	Hold	2,116,666	–	–	0.31%	11
2017 Q1	$6.39M	Buy	+2,116,666	New	+$6.01M	0.42%	11

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Prescott General Partners's LCTX Position: Q1 2025 in Review

Prescott General Partners sold out of Lineage Cell Therapeutics (LCTX) in Q1 2025, closing a stake of 386,000 shares — an estimated $194K sold.

Prescott General Partners first reported a position in LCTX in Q1 2017 and held it in 32 quarters. The position peaked at $6.39M in Q1 2017. 127 funds tracked by Wall St. Rank hold LCTX as of Q1 2025.

Prescott General Partners reported no remaining Lineage Cell Therapeutics position as of Q1 2025 after selling out during the quarter.
Prescott General Partners sold 386,000 Lineage Cell Therapeutics shares in Q1 2025, an estimated $194K.
Prescott General Partners first reported a position in Lineage Cell Therapeutics in Q1 2017 and held it in 32 quarters.
Prescott General Partners's Lineage Cell Therapeutics position peaked at $6.39M in Q1 2017.
127 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2025.

Based on Prescott General Partners's 13F filing for Q1 2025, filed 15 May 2025.